Volume | 12,633,394 |
|
|||||
News | - | ||||||
Day High | 43.05 | Low High |
|||||
Day Low | 41.88 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
42.58 | 41.88 | 43.05 | 43.02 | 42.57 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
100,517 | 12,633,394 | $ 42.59 | $ 537,994,258 | - | 39.91 - 66.38 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:03:25 | 1 | $ 43.00 | USD |
Bristol Myers Squibb (BMY) Options Flow Summary
Bristol Myers Squibb Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
86.99B | 2.02B | - | 45.01B | 8.03B | 3.97 | 10.84 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bristol Myers Squibb News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 41.83 | 43.05 | 40.70 | 41.62 | 12,406,064 | 1.08 | 2.58% |
1 Month | 45.21 | 45.715 | 39.91 | 42.05 | 15,115,477 | -2.30 | -5.09% |
3 Months | 51.76 | 54.475 | 39.91 | 45.93 | 13,620,766 | -8.85 | -17.10% |
6 Months | 50.52 | 55.035 | 39.91 | 48.96 | 15,665,230 | -7.61 | -15.06% |
1 Year | 64.79 | 66.38 | 39.91 | 52.62 | 13,622,465 | -21.88 | -33.77% |
3 Years | 67.82 | 81.435 | 39.91 | 62.64 | 11,734,310 | -24.91 | -36.73% |
5 Years | 46.20 | 81.435 | 39.91 | 60.81 | 12,331,271 | -3.29 | -7.12% |
Bristol Myers Squibb Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |